Skip to main content

Advertisement

SpringerLink
Log in

Stromal expression of carbonic anhydrase IX in esophageal cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Carbonic anhydrase IX (CA IX), a transmembrane glycoprotein, is known as an endogenous marker for hypoxia. Overexpressed in cancer-associated fibroblasts, CA IX has been reported to be associated with a poor outcome for a number of malignant tumors. Aim of this study was to investigate the role of CA IX in the tumor surrounding stroma of esophageal cancer.

Methods/patients

Stromal expression of CA IX in 361 formalin-fixed, paraffin-embedded specimens of invasive esophageal cancers, 206 adenocarcinoma (AC) and 155 squamous cell carcinoma (SCC), was investigated.

Results

In 42 cases (11.6 %), CA IX expression in the tumor surrounding stroma (AC 23 and SCC 19) was observed. Expression of CA IX correlated with the factors tumor stage (p < 0.001) and lymph node status (p = 0.008). Patients with CA IX expressed in the tumor surrounding stroma had a significant shorter disease-free survival (p = 0.007) and overall survival (p = 0.013).

Conclusion

In esophageal cancer, CA IX-expressing tumor stroma is associated with shorter survival. Inhibition of the tyrosine kinase CA IX might represent a new onset for therapies against esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200(4):429–47. doi:10.1002/path.1398.

    Article  PubMed  Google Scholar 

  2. Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer. 2011;6(1):209–17. doi:10.1097/JTO.0b013e3181f8a1bd.

    Article  Google Scholar 

  3. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839–49. doi:10.1038/nrc1477.

    Article  PubMed  CAS  Google Scholar 

  4. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother: CII. 2008;57(1):1–17. doi:10.1007/s00262-007-0365-5.

    Article  PubMed  CAS  Google Scholar 

  5. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9(10):2877–88.

    PubMed  CAS  Google Scholar 

  6. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001;61(17):6394–9.

    PubMed  CAS  Google Scholar 

  7. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2001;7(11):3399–403.

    CAS  Google Scholar 

  8. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001;61(21):7992–8.

    PubMed  CAS  Google Scholar 

  9. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21(3):473–82.

    Article  CAS  Google Scholar 

  10. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2002;8(8):2595–604.

    CAS  Google Scholar 

  11. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2001;19(16):3660–8.

    CAS  Google Scholar 

  12. Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT, et al. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer. 2011;72(3):294–302. doi:10.1016/j.lungcan.2010.10.006.

    Article  PubMed  Google Scholar 

  13. Kon-no H, Ishii G, Nagai K, Yoshida J, Nishimura M, Nara M, et al. Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer. 2006;54(3):409–18. doi:10.1016/j.lungcan.2006.08.017.

    Article  PubMed  Google Scholar 

  14. Cleven AH, van Engeland M, Wouters BG, de Bruine AP. Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol: Off J Int Soc Cell Oncol. 2007;29(3):229–40.

    CAS  Google Scholar 

  15. Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat. 2003;81(2):137–47. doi:10.1023/A:1025702330207.

    Article  PubMed  CAS  Google Scholar 

  16. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31(4):450–64.

    Article  PubMed  Google Scholar 

  17. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92(3):151–9. doi:10.1002/jso.20357.

    Article  PubMed  Google Scholar 

  18. Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev. 2010;36(3):235–48. doi:10.1016/j.ctrv.2009.12.009.

    Article  PubMed  CAS  Google Scholar 

  19. Birner P, Jesch B, Friedrich J, Riegler M, Zacherl J, Hejna M, et al. Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann Surg Oncol. 2011;18(12):3330–7. doi:10.1245/s10434-011-1730-3.

    Article  PubMed  Google Scholar 

  20. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34(12):1868–73. doi:10.1097/PAS.0b013e3181f8be17.

    Article  PubMed  Google Scholar 

  21. Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P. Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery. 2013;153(4):526–34. doi:10.1016/j.surg.2012.10.007.

    Article  PubMed  Google Scholar 

  22. Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P. Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clin Exp Metastasis. 2012;29(6):615–24. doi:10.1007/s10585-012-9475-3.

    Article  PubMed  CAS  Google Scholar 

  23. Breiteneder-Geleff S, Soleiman A, Horvat R, Amann G, Kowalski H, Kerjaschki D. Podoplanin—a specific marker for lymphatic endothelium expressed in angiosarcoma. Verh Dtsch Ges Pathol. 1999;83:270–5.

    PubMed  CAS  Google Scholar 

  24. Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res. 2001;21(4A):2351–5.

    PubMed  CAS  Google Scholar 

  25. Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, et al. Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol. 2007;2:8. doi:10.1186/1746-1596-2-8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Brockton NT, Klimowicz AC, Bose P, Petrillo SK, Konno M, Rudmik L, et al. High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. Oral Oncol. 2012;48(7):615–22. doi:10.1016/j.oraloncology.2012.01.018.

    Article  PubMed  CAS  Google Scholar 

  27. Nakao M, Ishii G, Nagai K, Kawase A, Kenmotsu H, Kon-No H, et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer. 2009;115(12):2732–43. doi:10.1002/cncr.24303.

    Article  PubMed  CAS  Google Scholar 

  28. Schoppmann SF, Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G, et al. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis. 2012;. doi:10.1007/s10585-012-9549-2.

    Google Scholar 

  29. Gieling RG, Williams KJ. Carbonic anhydrase IX as a target for metastatic disease. Bioorg Med Chem. 2012. doi:10.1016/j.bmc.2012.09.062.

    PubMed  Google Scholar 

  30. Shin HJ, Rho SB, Jung DC, Han IO, Oh ES, Kim JY. Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci. 2011;124(Pt 7):1077–87. doi:10.1242/jcs.072207.

    Article  PubMed  CAS  Google Scholar 

  31. Ito S, Ishii G, Hoshino A, Hashimoto H, Neri S, Kuwata T, et al. Tumor promoting effect of podoplanin-positive fibroblasts is mediated by enhanced RhoA activity. Biochem Biophys Res Commun. 2012;422(1):194–9. doi:10.1016/j.bbrc.2012.04.158.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

S.F. Schoppmann received an unrestricted research grant by Novartis.

Author information

Authors and Affiliations

  1. Gastroesophageal Cancer Unit, Department of Surgery, Upper-GI-Service, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    G. Jomrich, B. Jesch, K. Schwameis, M. Paireder, R. Asari & S. F. Schoppmann

  2. Clinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    P. Birner

Authors
  1. G. Jomrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Jesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Birner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Schwameis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Paireder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Asari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. F. Schoppmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. F. Schoppmann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jomrich, G., Jesch, B., Birner, P. et al. Stromal expression of carbonic anhydrase IX in esophageal cancer. Clin Transl Oncol 16, 966–972 (2014). https://doi.org/10.1007/s12094-014-1180-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1180-z

Keywords

Search

Navigation